
KalVista Pharma (KALV) Stock Forecast & Price Target
KalVista Pharma (KALV) Analyst Ratings
Bulls say
KalVista Pharmaceuticals Inc. is experiencing robust demand for its FDA-approved product, EKTERLY (sebetralstat), which has generated $49 million in sales since its approval and is projected to achieve $170.8 million in sales by 2026, significantly higher than previous estimates. The positive outlook is bolstered by an increase in prescribers, growing from 423 to 580 by year-end 2025, along with strong refill rates indicating higher than anticipated market acceptance and utilization. Additionally, the market research indicating that only 65% of hereditary angioedema (HAE) attacks are currently treated with injectable therapies suggests substantial growth potential for EKTERLY as the on-demand HAE segment is projected to grow from $700 million to $1.5 billion.
Bears say
KalVista Pharmaceuticals faces a negative outlook primarily due to anticipated headwinds in the first quarter of 2026, linked to insurance reauthorizations and possibly elevated sales in prior periods influenced by year-end holiday demand. The company's revenue expectations for EKTERLY (sebetralstat) may not be met as a result of concerns regarding market size, penetration rates, and pricing, which pose significant risks to achieving projected sales. Additionally, the potential failure to secure adequate capital resources raises further uncertainty regarding the company's ability to finance operations and continue program development and commercialization activities.
This aggregate rating is based on analysts' research of KalVista Pharma and is not a guaranteed prediction by Public.com or investment advice.
KalVista Pharma (KALV) Analyst Forecast & Price Prediction
Start investing in KalVista Pharma (KALV)
Order type
Buy in
Order amount
Est. shares
0 shares